CK Life Sciences International, the biotech unit controlled by the Li Ka-shing family, is expected to post a loss for last year due to an increase in R&D spending and a decline in the value of its vineyard assets.
The company may report an annual loss of HK$126.6 million (US$16.3 million), compared with a profit of HK$17.3 million in 2023, CK Life said in a statement to the Hong Kong stock exchange on Thursday night. The company will announce its results on March 18.
